Cisplatin (DDP), a widely used chemotherapeutic drug in cancer treatment, causes oxidative
stress, resulting in cancer cachexia and skeletal muscle atrophy. This study investigated the …

Skeletal muscle atrophy is an important feature of cancer cachexia, which can be induced by
chemotherapy, and affects the survival and quality of life of cancer patients seriously. No …

Cisplatin (DDP) is a commonly used chemotherapy drug, but DDP can cause skeletal
muscle atrophy and cachexia. This study combined the DDP-induced C2C12 myotube …

Cisplatin (DDP) is widely used in cancer treatment, but DDP can cause skeletal muscle
atrophy and cachexia. This study explored the effect and mechanism of daidzein (DAI) in …

Background: Cisplatin is a widely used anticancer drug in clinic, but it has a damaging effect
on skeletal muscle cells. Clinical observation showed that Yiqi Chutan formula (YCF) had a …

Both quercetin and leucine have been shown to exert moderately beneficial effects in
preventing muscle atrophy induced by cancers or chemotherapy. However, the combined …

Cisplatin induces anorexia, weight loss, loss of adipose tissue, skeletal muscle atrophy, and
serious adverse effects that can cause premature termination of chemotherapy. The aim of …

Silibinin was reported to have high cyto-toxicity in many malignant cell lines, however, it
showed low cyto-toxicity in treatment of human melanoma A375-S2 cells and even protected …

Cisplatin (CIS) is a chemotherapeutic agent known to induce cachexia. CIS causes the
atrophy of skeletal muscle. Thymoquinone (TQ) is a powerful antioxidant with an anti …

Growing evidence indicates that silibinin (SLB), a main component extracted from Chinese
herb Silybum marianum, can effectively antagonize doxorubicin (DOX) induced myocardial …